Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of post-operative atrial fibrillation after elective CABG
IRCT20230110057098N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Empagliflozin plus usual treatment with Placebo plus usual treatment (2 arms). Primary endpoints: Rate of post-operative atrial fibrillation, Hospitalization length and 5 more. Started Apr 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20230110057098N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230110057098N1.